Scholar Rock Q2 Loss Narrows Slightly; Cash Runway Extended Ahead of September PDUFA
SRRK sits 93% above its 52-week low of $27.07.
Summary
Scholar Rock reported a slightly narrower Q2 loss and extended its cash runway into 2027, positioning for the September 30 PDUFA decision on apitegromab. The company raised significant capital through its ATM program, ending the quarter with $492 million in cash.
Key Events · Earnings and Guidance · SRRK
-
Q2 Loss Narrows Slightly
Net loss of $109.9M ($0.84/share) vs. $110.0M ($0.98/share) a year ago, with R&D expenses down 6.7% and G&A up 2.0%.
-
Cash Runway Extended
Cash, equivalents, and marketable securities of $492.1M as of June 30, 2026, including $62.8M net proceeds from the ATM program, extending runway into 2027.
-
PDUFA Date September 30, 2026
FDA review of apitegromab BLA for SMA is advancing with two fill-finish facilities; approval decision expected by September 30, 2026.
-
Pipeline Progress
Phase 2 FORGE study in FSHD initiated; Phase 1 study of SRK-439 ongoing with topline data expected late 2026.
Analysis · SRRK · Life Sciences
Scholar Rock reported a slightly narrower Q2 loss and extended its cash runway into 2027, positioning for the September 30 PDUFA decision on apitegromab. The company raised significant capital through its ATM program, ending the quarter with $492 million in cash. The FDA review is advancing with two fill-finish facilities, providing a backup path to approval. The initiation of the Phase 2 FORGE study in FSHD and progress on SRK-439 add pipeline depth. The stock is near its 52-week high, reflecting optimism around the upcoming catalyst.
At the time of this filing, SRRK was trading at $52.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $27.07 to $58.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.